Bethlehem, United States
Ilico Genetics is a biotechnology startup, founded in 2022 and headquartered in the United States. It is a Spin Off of Pontificia Universidad Católica de Chile and is pioneering the development of a groundbreaking methylated DNA-based molecular test tailored for the early detection of gastric cancer. This innovative test is designed to identify tumors in the stomach or lesions that may progress to gastric cancer years before the conventional Esophagogastroduodenoscopy (EGD) method, which is considered the gold standard in detection. The test, which requires only a blood sample, can detect tumors and monitor their cumulative presence over time, even in the absence of symptoms. The potential impact of this technology on early diagnosis and intervention in gastric cancer cannot be overstated, with significant implications for improving patient outcomes and survival rates.
As of now, there is no publicly disclosed information regarding the last investment round or the participating investors for Ilico Genetics. Nonetheless, given the pioneering nature of its technology and the critical need for improved early detection methods in cancer diagnostics, the startup is likely to attract attention from venture capital firms and investors specializing in the biotechnology and healthcare industries.
